中国164,137名女性中的HPV患病率表现出一些独特的流行病学特征。
The prevalence of HPV among 164,137 women in China exhibited some unique epidemiological characteristics.
发表日期:2023 Nov 10
作者:
Qiong Chen, Wanglei Qu, Yu Zhao, Li Shu, Yi Wang, Xiangnan Chen
来源:
Immunity & Ageing
摘要:
HPV 感染的持续存在是宫颈癌发生的重要病因。本研究调查了温州地区 164,137 名未接种疫苗的女性中人乳头瘤病毒(HPV)的患病率和基因型分布,旨在为临床宫颈癌筛查和 HPV 疫苗接种策略提供指导。本回顾性研究共纳入了 164,137 名未接种疫苗的女性。女性,包括 2015 年至 2020 年招募的 118,484 名门诊患者和 45,653 名健康女性受试者。从这些参与者身上收集宫颈脱落细胞用于后续 DNA 提取。提取的DNA样本采用荧光原位杂交方法进行分析,检测出27种HPV基因型。HPV总体患病率为17.35%;门诊组的患病率为 19.10%,健康女性组的患病率为 12.82%。在门诊组中,最常见的 5 种 HPV 基因型为 HPV 52、58、16、53 和 61。在健康女性组中,最常见的 5 种 HPV 基因型为 HPV 52、53、58、61。和 81。此外,据估计,10 至 19 岁之间的人群 (44.65%) 和 60 至 69 岁之间的人群 (27.35%) 的 HPV 感染率最高。区域很大;因此,实施科学合理的疫苗接种等临床干预措施势在必行。应进行常规宫颈筛查,以防止因高危 HPV 持续感染而导致宫颈上皮内瘤变,特别是患有妇科疾病的女性和 60 岁以上的女性。© 2023。作者。
The persistence of HPV infection is a significant etiological factor in the development of cervical cancer. The present study investigated the prevalence and genotype distribution of human papillomavirus (HPV) in a cohort of 164,137 unvaccinated women from Wenzhou, aiming to provide guidance for clinics in the cervical cancer screening and HPV vaccination strategies.The present retrospective study included a total of 164,137 women, comprising 118,484 outpatients and 45,653 healthy female subjects recruited from 2015 to 2020. Cervical exfoliated cells were collected from these participants for subsequent DNA extraction. The extracted DNA samples were underwent analysis using a fluorescence in situ hybridization method, encompassing the detection of 27 HPV genotypes.The overall prevalence of HPV was 17.35%; this corresponded to a prevalence of 19.10% in the outpatient group and 12.82% in the healthy female group. Among the outpatient group, the five most prevalent HPV genotypes were identified as HPV 52, 58, 16, 53, and 61. In the healthy female group, the five most common HPV genotypes were found to be HPV 52, 53, 58, 61, and 81. Additionally, it was estimated that the highest rate of HPV infection occurred among individuals aged between 10 and 19 years old (44.65%) and those aged between 60 and 69 years old (27.35%).The prevalence of HPV in this region is substantial; therefore, it is imperative to implement scientifically sound and rational clinical interventions such as vaccination. Routine cervical screening should be performed to prevent the development of cervical intraepithelial neoplasia resulting from persistent infection with high-risk HPV, particularly in women with gynecological diseases and those over 60 years old.© 2023. The Author(s).